Takashi Kadowaki
Tokyo University · Professor, Department of Metabolic Diseases, Graduate School of Medicine, the University of Tokyo.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Takashi Kadowaki as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:09 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02354222 · Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)Tanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02354235 · Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)Tanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02314637 · Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic PatientsTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT02220907 · Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph4NCT02081599 · Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01301833 · Long-term Safety Study of MP-513 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT01026194 · Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00998881 · Monotherapy Study of MP-513 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph3NCT00974090 · Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes Mellitus · study director
- Ph2NCT00628212 · Efficacy and Safety Study of MP-513 in Patients With Type 2 DiabetesTanabe Pharma Corporation · completed · Type 2 Diabetes · study director
- Ph4NCT00301392 · Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)Tokyo University · completed · Diabetes Mellitus, Glucose Intolerance · study chair
- N/ANCT00300976 · The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular DiseasesJapan Foundation for the Promotion of International Medical Research Cooperation · unknown · Cardiovascular Diseases, Diabetes Mellitus, Type 2 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:09 UTC. The ranking covers the 200 most relevant of 82 PubMed records, and a shared surname and initials can bring in a namesake. All 82 on PubMed
- Empagliflozin in Patients with Chronic Kidney Disease.N Engl J Med · 20232,218 citationsRCR 280.0
- 457 citationsRCR 20.8
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.Lancet Diabetes Endocrinol · 2022285 citationsRCR 24.0
- Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.Lancet Diabetes Endocrinol · 2017263 citationsRCR 10.2
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.Clin Cancer Res · 2016161 citationsRCR 5.1
- Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians.Diabetes Care · 2014129 citationsRCR 4.4
- Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.Lancet Diabetes Endocrinol · 2022113 citationsRCR 9.4
- Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Clinical Trial.Am J Respir Crit Care Med · 2022101 citationsRCR 9.9
- Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.N Engl J Med · 2025100 citationsRCR 27.3
- Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men.Am J Hypertens · 200494 citationsRCR 2.8